Your browser doesn't support javascript.
loading
Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides.
Culver, K W; Hsieh, W T; Huyen, Y; Chen, V; Liu, J; Khripine, Y; Khorlin, A.
Afiliação
  • Culver KW; Novartis Pharmaceuticals Corp., East Hanover, NJ, 07936, USA. ken.culver@pharma.novartis.com
Nat Biotechnol ; 17(10): 989-93, 1999 Oct.
Article em En | MEDLINE | ID: mdl-10504700
ABSTRACT
A sequence-specific genomic delivery system for the correction of chromosomal mutations was designed by incorporating two different binding domains into a single-stranded oligonucleotide. A repair domain (RD) contained the native sequence of the target region. A third strand-forming domain (TFD) was designed to form a triplex by Hoogsteen interactions. The design was based upon the premise that the RD will rapidly form a heteroduplex that is anchored synergistically by the TFD. Deoxyoligonucleotides were designed to form triplexes in the human adenosine deaminase (ADA) and p53 genes adjacent to known point mutations. Transfection of ADA-deficient human lymphocytes corrected the mutant sequence in 1-2% of cells. Neither the RD or TFD individually corrected the mutation. Transfection of p53 mutant human glioblastoma cells corrected the mutation and induced apoptosis in 7.5% of cells.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Oligonucleotídeos / Adenosina Desaminase / Cromossomos Humanos / Mutação Puntual Idioma: En Ano de publicação: 1999 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Oligonucleotídeos / Adenosina Desaminase / Cromossomos Humanos / Mutação Puntual Idioma: En Ano de publicação: 1999 Tipo de documento: Article